Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

NCT01495988 is registered in ClinicalTrials.gov with Melanoma Research Foundation Breakthrough Consortium as lead sponsor.

NCT NCT01495988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01495988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Lead sponsor
Melanoma Research Foundation Breakthrough Consortium
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2013
Completion date
June 30, 2016
Enrollment
10 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, metastatic melanoma